Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides dr...
Kopran reported revenue of 6.10 billion INR for fiscal year 2024, up 11.3% from fiscal year 2023, and net income of 509.56 million INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 1.94 billion INR, up 16.9% from a year before. India was its largest region in fiscal year 2025, with 32% of revenue. Its market capitalization was 12.13 billion INR as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2024; market data as of October 9, 2026.
No profile data available.